Bintrafusp alfa GSK fails to meet primary endpoint in biliary tract cancer study
In the Phase II INTR@PID BTC 047 study, this TGF-β and PD-L1 inhibitor provided an objective response rate of 10.1% in the second line setting, which did not meet the pre-defined threshold for efficacy, meaning that regulatory filing will not be pursued.
Source:
Biospace Inc.